Medpace Holdings, Inc. (NASDAQ:MEDP)
| Market Cap | 16.36B+20.7% |
| Revenue (ttm) | 2.78B+24.7% |
| Net Income | 491.50M+17.5% |
| EPS | 17.07+26.9% |
| Shares Out | 27.91M |
| PE Ratio | 33.71 |
| Forward PE | 30.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181,154 |
| Open | 587.82 |
| Previous Close | 590.89 |
| Day's Range | 577.47 - 587.89 |
| 52-Week Range | 373.00 - 677.90 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 606.38(+3.42%) |
| Earnings Date | Oct 28, 2026 |
About MEDP
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MEDP stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of MEDP by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| David J. TaylorHouse / R | Purchase$1.00K – $15.00K | May 14, 2026 |
| David J. TaylorHouse / R | Purchase$1.00K – $15.00K | Feb 25, 2026 |
| David J. TaylorHouse / R | Purchase$1.00K – $15.00K | Jan 28, 2026 |
| David J. TaylorHouse / R | Sale$1.00K – $15.00K | Jan 15, 2026 |
| David J. TaylorHouse / R | Sale$1.00K – $15.00K | Jul 22, 2025 |
| Michael GuestHouse / R | Purchase$1.00K – $15.00K | Nov 12, 2023 |
Recently reported changes in MEDP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MEDP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MEDP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MEDP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MEDP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MEDP
| ETF | Est. Holding Size |
|---|---|
| IJHiShares Core S&P Mid-Cap ETF | $466.05M |
| VTIVanguard Morningstar Total Stock Market ETF | $419.67M |
| VBVanguard Morningstar Small-Cap ETF | $303.08M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $175.39M |
| XMHQInvesco S&P MidCap Quality ETF | $175.20M |
| VXFVanguard Extended Market ETF | $150.04M |
Estimated from each fund’s disclosed top holdings × AUM
MEDP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MEDP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score